Form 4: Eli Lilly EVP Seymour's Stock Transactions

Eli Lilly and Company's EVP of Global Quality, Melissa Seymour, reported the acquisition and disposition of common stock and restricted stock units.

Summary

• Melissa Seymour, Executive Vice President of Global Quality at Eli Lilly and Company, reported transactions involving company stock.
• On August 1, 2025, Seymour acquired 952 shares of common stock at a price of $0.
• Concurrently, 426.92 shares of common stock were disposed of at a price of $740.07, likely for tax withholding related to the RSU vesting.
• The transactions also involved the acquisition of 952 restricted stock units (RSUs) on August 1, 2025.
• Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
• Following these transactions, Seymour beneficially owns 525.08 shares of common stock and 1,933 restricted stock units.
• The restricted stock units are scheduled to vest in three installments: 952 units on August 1, 2025, 981 units on August 1, 2026, and 952 units on August 1, 2027.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The filing indicates routine executive compensation and stock management, including RSU vesting and associated tax-related sales, which are generally positive for executive retention and alignment with shareholder interests. The transactions are pre-planned under a 10b5-1 plan, indicating transparency and compliance.

Positives

• The acquisition of 952 shares of common stock at $0 indicates the vesting of restricted stock units, which is a form of compensation for the executive.
• The existence of a Rule 10b5-1(c) plan demonstrates pre-planned and transparent trading activity by the executive.

Negatives

• The disposition of 426.92 shares of common stock at $740.07, likely for tax withholding, reduces the executive's direct shareholding.

Future Outlook

The filing does not provide forward-looking statements or guidance beyond the vesting schedule for restricted stock units.

Industry Context

This Form 4 filing details routine executive compensation and stock transactions, which are common across publicly traded companies, particularly in the pharmaceutical industry, as part of executive incentive programs. It does not provide broader industry context or trends.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency on executive stock ownership and compensation, which can influence investor confidence.
• Employees: Reflects standard executive compensation practices, potentially impacting morale and retention strategies.

Next Steps

• Future vesting of restricted stock units on August 1, 2026 (981 units) and August 1, 2027 (952 units).

Key Dates

Recommendation

This Form 4 filing details routine executive stock transactions related to compensation and vesting of restricted stock units. It does not contain new material information that would fundamentally alter the investment thesis for Eli Lilly and Company. The transactions are pre-planned and expected, thus not warranting a change in investment recommendation based solely on this filing.

Keywords

Eli Lilly, LLY, Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Executive Compensation, Melissa Seymour, Corporate Governance